CPT 96413: Intravenous Chemotherapy Infusion, Initial Hour
Medicare pays $139 and commercial payers pay $386 on average nationally for this procedure.
CPT code 96413 describes the initial hour of intravenous chemotherapy administration using infusion technique for anti-neoplastic agents; this service represents professional delivery of cytotoxic or targeted chemotherapy by IV infusion, typically provided in oncology or infusion center settings and as an outpatient therapeutic procedure for cancer treatment.
For related coverage guidance, see recent payer policy updates: Bendamustine Products Coverage Criteria, T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and Romidepsin, Brentuximab Vedotin (Adcetris®) Coverage Criteria.
Customize your policy alerts
Sign up for cpt 96413 policy alerts
Get alerted when payer policies referencing 96413 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Medicare's national mean for CPT 96413 sits at $139.20, substantially below BUCA's average commercial mean of $385.80, indicating a roughly $246.60 gap between public and that commercial benchmark. This spread highlights how commercial contracts can pay multiple times Medicare levels for the same infusion service, with BUCA positioned near the upper-middle of commercial averages.
Dispersion (P75−P25) varies meaningfully across payers. Blue Cross Blue Shield shows the widest interquartile spread at $244.40 ($598.70−$354.30), followed by BUCA at $186.40 ($460.30−$263.90). Aetna and UnitedHealth Group are tighter at $136.20 and $123.00 respectively, while Cigna's spread is $145.10. These differences reflect greater variability in negotiated commercial rates versus relatively narrow Medicare locality variation.